April 6, 2018April 6, 2018

European Regulators Agree to Review Aradigm’s Bronchiectasis Bacteria Therapy

News

The European Medicines Agency has agreed to review Aradigm Corporation’s Linhaliq as a treatment for non-cystic fibrosis bronchiectasis patients with chronic Pseudomonas aeruginosa lung infections. If the agency recommends its approval, ... Read more

March 13, 2018March 13, 2018

Aradigm Asks EU to Approve Linhaliq for Bronchiectasis Patients’ Bacterial Infections

News

Aradigm Corporation has submitted a marketing authorization request to the European Medicines Agency (EMA) for Linhaliq as a treatment for non-cystic fibrosis bronchiectasis (NCFBE) patients who with a chronic Pseudomonas aeruginosa bacterial ... Read more